

# Access to antiviral drugs for treating HCV for HIV-positive patients in Russia: results and recommendations of the registration, policy and procurement analysis

**Babikhina Ksenia**

«Treatment Preparedness Coalition»

[office@itpcru.org](mailto:office@itpcru.org)

[itpcru.org](http://itpcru.org)


AIDS 2016 | 18-22 July 2016 | Durban, South Africa

- Monitoring of drug procurement since 2010, HCV procurement since 2012
- Coverage of the whole country (85 regions (entities) in Russian Federation)
- Around 5000 tenders annually
- Using specialized personnel for analysis the monitoring's results
- The results are presented at national-level conferences
- Annual reports

## HCV. The purposes

- Understand how many people can receive HCV treatment;
- How much money is spent on purchasing HCV;
- Which drugs are procured and which quantities;
- Compare with the international recommendation;
- Develop recommendation for improving the HCV treatment landscape.

# Prevalence of chronic hepatitis C in Russia, 2015



Expert estimates - **at least 5 million people with HCV**

Officially registered - **600 000 people**

Co-infected with HIV and HCV - **at least 200 000 people**

Total number of patients who could receive a therapy for treating HCV is **5 000 – 10 000 people**

Less than 1 % of the total estimated number of people with HCV

2.5 % co-infected patients

## Registered drugs

- Data of the website [grls.rosminzdrav.ru](http://grls.rosminzdrav.ru) to HCV drugs registered in Russia in 2015:

INN	Note
<b>Peg-inf 2a</b> («Pegasys»)	Essential Medicines List / Decree 1438
<b>PegInf 2b</b> («PegIntron», «PegAltevir»)	Essential Medicines List / Decree 1438
<b>CePegInf 2b</b> («Algeron»)	Essential Medicines List
<b>Simeprevir</b> («Sovriad»/ «Olysio»)	Essential Medicines List (included in 2016)
<b>Daclatasvir</b> («Daklinza»)	registered in 2015
<b>Asunaprevir</b> («Sunvepra»)	registered in 2015
<b>Ombitasvir/paritaprevir/ritonavir+Dasabuvir</b> («Viekira Pak»)	registered in 2015
<b>Sofosbuvir</b> («Sovaldi»)	registered in 2016
<b>Narlaprevir</b> («Narlaprevir»)	registered in 2016
<b>Telaprevir</b> («Incivo»)	Lists of Essential Medicines in Russia (excluded in 2016)
<b>Boceprevir</b> («Victrelis»)	registered in 2013

# Metodology

List of registered drugs → [www.zakupki.gov.ru](http://www.zakupki.gov.ru)



874 contracts concluded in 2015

- 3 INN for PegINF
- 6 INN for DAAs

INN

Treatment duration

Ce/PEG-INF

48 weeks

SMV, TPV, 3D

12 weeks

BOC

44 weeks (according to Russian recommendation)

DCV, ASV

24 weeks

## Monitoring and analysis results


- Total sum of the contracts = ~42 mln \$

Total number of patients: 5 100-9 300

PEG-INF patients ~4100 - 8200



DAAs patients ~1 000

Courses



■ PEG-INF ■ DAAs

## Treatment regimens in Russia 2015






## The price for the treatment course of DAAs 2016

INN	average weighted price per pack, \$	average weighted price per course, \$
Sofosbuvir	3 192	12 weeks – 9 576
3D	4 700	12 weeks – 14 100
Daclatasvir	1 860	12 weeks – 5 580 24 weeks - 11 160
Asunaprevir	190	24 weeks – 1 140
Simeprevir	3 400	12 weeks – 10 200
Boceprevir	1 190	44 weeks (Russian recommendation) – 13 090
Narlaprevir	-	-

## Trend in procurement value of DAAs 2013-2016



## **Conclusions**

1. The majority of HIV/HCV coinfecting patients have still receive PEG-IFN-based therapy
2. None of the DAAs are included in Decree No 1438
3. Sofosbuvir/ledipasvir is still not registered in Russia
4. High prices of DAAs – range of 10,000 – 15,000 USD
5. Clear trend towards DAAs
6. Sofosbuvir and several inf-free regimens were registered in Russia 2015-2016
7. Launching regional programmes for treating HCV

## **Recommendation**

1. Update the regulatory framework in the field of HCV to include DAAs (SOF+DCV, SOF+SIM, 3D, SOF/LDV etc)
2. Include DAAs in the Essential Medicines List and Decree No 1438 for federally funded
3. Price reduction on DAAs, including opportunities provided by flexibilities of TRIPS